Dr. John P. Seibyl, MD
Nuclear Medicine Specialist
60 Temple Street Suite 8A New Haven Connecticut, 06510About
John P. Seibyl, MD, is a nuclear medicine specialist who serves as CEO, Co-Founder and Senior Scientist of the Institute for Neurodegenerative Disorders in New Haven, Connecticut, a premier Parkinson's and Alzheimer's brain imaging research center, running the largest brain imaging clinical trials in the world for assessment of neuroprotective drugs. Dr. Seibyl co-founded the Institute with Dr. Ken Marek. IND is comprised of an accomplished team of physician investigators, study coordinators, neuropsychologists and imaging technologists. Furthermore, he was the President and Co-founder of Molecular Neuroimaging LLC. Established in 2000, Molecular NeuroImaging LLC provides neuroimaging research services to the pharmaceutical and biotech industries. In 2016, MNI (Molecular NeuroImaging) was acquired by Invicro and now operates as a wholly owned subsidiary of Invicro. Dr. Seibyl has an impressive professional journey that spans more than twenty-five years and is an international expert on PET and SPECT imaging for neurodegenerative disorders. Along with Dr. Marek he has directed and continues to direct several international multicenter imaging studies. An expert in brain imaging, Dr. Seibyl’s other interests include coordinating international multicenter PET imaging trials in Alzheimer's for both novel diagnostics and for application of imaging biomarkers in therapeutic trials. Dr. Seibyl leads an active human imaging biomarker research program where novel brain targets are evaluated with both PET and SPECT. Prior to his current endeavors, he served as Director of the NeuroSPECT Center at Yale University, Chief of the Section of Nuclear Medicine and Director of the Yale PET Center (1996-2001), and Associate Clinical Professor of Diagnostic Radiology at Yale University School of Medicine. Dr. Seibyl has won numerous grants and contracts over the course of his career in brain imaging and served on the editorial board of the European Journal of Nuclear Medicine.
Dr. John P. Seibyl, MD's Videos
Education and Training
Case Western Reserve University School of Medicine Medical Degree 1986
Board Certification
Psychiatry by the American Board of Psychiatry and Neurology
Nuclear Medicine by the American Board of Nuclear Medicine
Provider Details
Expert Publications
Data provided by the National Library of Medicine- Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans.
- Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.
- Effect of injection time on postictal SPET perfusion changes in medically refractory epilepsy.
- Single-photon emission computed tomography of the dopamine transporter in parkinsonism.
- Behavioral changes and [123I]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine.
- Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans.
- Reproducibility of serial peri-ictal single-photon emission tomography difference images in epilepsy patients undergoing surgical resection.
- Decreased cerebral blood flow during seizures with ictal SPECT injections.
- Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT.
- Test-retest reproducibility of extrastriatal dopamine D2 receptor imaging with [123I]epidepride SPECT in humans.
- Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT.
- SPECT imaging with the D(4) receptor antagonist L-750,667 in nonhuman primate brain.
- Ratio-images calculated from interictal positron emission tomography and single-photon emission computed tomography for quantification of the uncoupling of brain metabolism and perfusion in epilepsy.
- Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates.
- Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers.
Areas of expertise and specialization
Faculty Titles & Positions
- Associate Clinical Professor of Diagnostic Radiology, Yale University -
- Local, Regional, National, and International Public Speaking -
Professional Memberships
- Society of Nuclear Medicine and Molecular Imaging
- Brain Imaging Council
- Society of Nuclear Medicine-New York Chapter
Fellowships
- Yale New Haven Hospital Nuclear Medicine
Fellowships
- Yale School of Medicine (Nuclear Medicine)
Professional Society Memberships
- Society of Nuclear Medicine and Molecular Imaging (Former President, 2007-2008), Brain Imaging Council (President, 2012-2013), Society of Nuclear Medicine-New York Chapter (Former President)
Articles and Publications
Has been Published
What do you attribute your success to?
His ability and interest to continue learning, and finding new details about the brain.
Hobbies / Sports
- Distance Running
Favorite professional publications
- Journal of Nuclear Medicine
Dr. John P. Seibyl, MD's Practice location
Dr. John P. Seibyl, MD's reviews
Write ReviewPatient Experience with Dr. Seibyl
Media Releases
Get to know Nuclear Medicine Physician Dr. John P. Seibyl, who serves patients in New Haven, Connecticut.
Dr. Seibyl, a board-certified nuclear medicine physician, serves as the Executive Director, Senior Scientist, and Chairman of the Board at the Institute for Neurodegenerative Disorders in New Haven, Connecticut.
In 2001, he co-founded the Institute for Neurodegenerative Disorders alongside Dr. Kenneth Marek as a non-profit, independent clinical imaging research facility. Their goal was to create a unique clinical research company that combines excellence in clinical neuroscience with state-of-the-art imaging to develop improved tools for the diagnosis and treatment of Parkinson’s disease, Alzheimer’s disease, and other neurologic conditions. Along with a team of expert researchers, the facility is actively involved in novel clinical studies, offering the potential to slow neurological disease or even restore neurological function.
Recognized as an international expert on PET and SPECT imaging for neurodegenerative disorders, Dr. Seibyl also serves as the Managing Director of Molecular NeuroImaging, a Division of inviCRO, and as the Chairman of the Board & President of the Trinity Institute For Applied Neuroscience And Spirituality.
Prior to his current endeavors, he served as the Co-Founder & President of Molecular NeuroImaging, the Director of the NeuroSPECT Center at Yale University, the Chief of the Section of Nuclear Medicine and Director of the Yale PET Center (1996-2001), and an Associate Clinical Professor of Diagnostic Radiology at Yale University School of Medicine.
After earning his medical degree from the Case Western Reserve University School of Medicine in 1986, Dr. Seibyl trained as a post-doctoral fellow in the Department of Psychiatry at Yale University, where he won the Seymour Lustman Research Prize for two consecutive years. He then joined the faculty as an Assistant Professor upon the completion of his training.
While on the psychiatry faculty, his interest in brain imaging led to his returning for a training fellowship in nuclear medicine at Yale under Dr. Paul Hoffer. He was recruited to the Diagnostic Radiology faculty and was appointed the Director of the NeuroSPECT Center, a clinical brain imaging research lab in the Section of Nuclear Medicine. He subsequently became Chief of the Section of Nuclear Medicine and Director of the Yale / VA PET Center.
The doctor is board-certified in nuclear medicine by the American Board of Nuclear Medicine, which certifies physicians as specialists in the practice of nuclear medicine. In addition, he is board-certified in psychiatry by the American Board of Psychiatry and Neurology, which is a not-for-profit corporation dedicated to serving the public interest and the professions of psychiatry and neurology by promoting excellence in practice through certification and maintenance of certification processes.
To stay current with the latest advances in his field, Dr. Seibyl remains a distinguished member of the Society of Nuclear Medicine and Molecular Imaging, the Brain Imaging Council, and the Society of Nuclear Medicine-New York Chapter – from all of which he is a former President. He was awarded the 2015 Kuhl-Lassen Award by the Society of Nuclear Medicine and Molecular Imaging for outstanding contributions to the advancement of molecular imaging.
Nuclear medicine is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear medicine physicians are medical specialists who use tracers, usually radiopharmaceuticals, for diagnosis and therapy. Nuclear medicine procedures are the major clinical applications of molecular imaging and molecular therapy.
With an impressive professional journey that spans over three decades, Dr. Seibyl has won numerous grants and contracts in the context of his work in brain imaging, publishing over 250 articles, book chapters, and case reports. He serves on the editorial board of the European Journal of Nuclear Medicine and is a frequent reviewer for top-tier nuclear imaging journals.
Furthermore, he serves on international panels for his work in neurodegenerative disease imaging, working closely with Dr. Marek to establish the NeuroSPECT Center as the premier Parkinson’s disease brain imaging research center in the world. Recent projects include the development of a web-based normal brain image database, and on-going work applying brain imaging techniques and analytic methods to improve the diagnosis and assessment of disease status in patients with neurodegenerative diseases.
With a passion for his field, Dr. Seibyl attributes his success to his ability and interest to continue learning and find new details about the brain. In his free time, he enjoys distance running.
Recommended Articles
- Calorie Counts of Some Common Foods
When it comes to weight loss, the one question that is on most people's minds is how many calories are in the drink you just had or how many calories are there in a pound of eggplant?One of the reasons why this question is not just vital but important lies in the fact that your body processes the...
- What Is an Antitussive?
A cough is described as a sudden explosive exhalation of air. It is basically a body's defense mechanism to protect and clear the airways from inhaled foreign materials. People may also voluntarily or spontaneously cough. Coughs often vary and may be characterized by productive (chesty or wet) or...
- What Is a Heel Spur?
A heel spur refers to a small, pointed calcaneus outgrowth from the underside of the heel. The outgrowth may be seen under the heel or at the back of the heel. Both conditions may remain painless, or it can cause pain while pressure is applied to the ball of the foot.Patients may not have any...
- What Causes Obesity?
A person who has a body weight that is 20% or more than the designated normal weight is considered to be obese. Obesity actually refers to the excess amount of fat present in the body. Based on the statistical measurement of Body Mass Index or BMI, obesity refers to BMI above 30. BMI is a...
- New Multiple Sclerosis Treatment, Ocrevus, Slows Down Disease Progression
In 2017, the United States Food and Drug Administration (USFDA) approved the drug – Ocrevus (ocrelizumab) – as a treatment for both relapsing and progressive forms of multiple sclerosis. ...
- The History of Muscular Dystrophy
What is muscular dystrophy?Muscular dystrophy is an inherited disorder, which is often characterized by a progressive type of muscular degeneration and weakness. There are several types of muscular dystrophy, wherein each type eventually leads to an increased disability, strength loss, and potential...